|
|
| (19 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{Suicidal ideation}}
| |
|
| |
|
| {{CMG}}; {{AE}}
| |
| ==Overview==
| |
|
| |
| ==Epidemiology and Demographics==
| |
|
| |
|
| |
| ===Prevalence===
| |
| *The prevalence of suicidal ideation is approximately 18490 per 100,000 individuals worldwide.
| |
|
| |
| ===Age===
| |
| Suicide is the third leading cause of death among
| |
| persons aged 10-14, the second among persons
| |
| aged 15-34 years, the fourth among persons aged
| |
| 35-44 years, the fifth among persons aged 45-54
| |
| years, the eighth among person 55-64 years, and the
| |
| seventeenth among persons 65 years and olde
| |
| ===Race===
| |
| *There is no racial predilection to [disease name].
| |
| *[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
| |
| ===Gender===
| |
| *[Disease name] affects men and women equally.
| |
| *[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
| |
| ===Region===
| |
| *The majority of [disease name] cases are reported in [geographical region].
| |
|
| |
| *[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
| |
|
| |
| ===Developed Countries===
| |
|
| |
| ===Developing Countries===
| |
|
| |
| ==References==
| |
| {{Reflist|2}}
| |
|
| |
| {{WH}}
| |
| {{WS}}
| |